Related Experiment Videos
Radiosensitizer conjugation to the carcinoma 19-9 monoclonal antibody
Abstract:
Misonidazole was covalently conjugated (3-68 mol drug/mol antibody) to 19-9 monoclonal antibody directed against a colorectal carcinoma tumor-associated antigen as a method for targeting radiosensitizing agents. This attachment was accomplished by the mixed anhydride method using the hemisuccinate derivative of misonidazole. Evaluation of conjugates in vitro shows a loss of antibody binding activity with increasing loading levels; however, significant binding activity is retained even at relatively high sensitizer/antibody ratios. This observation was consistent in three binding assays: a competitive radioimmunoassay; an enzyme immunoassay; and an affinity column assay. From these studies, it was concluded that the optimal loading factor for misonidazole-antibody conjugates, when it is used for immunochemotherapy lies between 8 and 15. In vitro release studies indicated that conjugates are hydrolytically stable (t1/2 = 4 days) under physiological conditions.
Insights
Researchers conjugated misonidazole, a radiosensitizing agent, to a colorectal cancer antibody. The resulting conjugates showed retained antibody binding activity, suggesting potential for targeted immunochemotherapy.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Colorectal carcinoma exhibits specific tumor-associated antigens.
- Targeting radiosensitizing agents to tumors can enhance cancer therapy.
- Monoclonal antibodies offer specific tumor targeting capabilities.
Purpose of the Study:
- To conjugate misonidazole (a radiosensitizer) to the 19-9 monoclonal antibody.
- To evaluate the binding activity and stability of misonidazole-antibody conjugates.
- To determine the optimal loading factor for immunochemotherapy applications.
Main Methods:
- Covalent conjugation of misonidazole to 19-9 monoclonal antibody using the mixed anhydride method.
- Evaluation of conjugate binding activity using competitive radioimmunoassay, enzyme immunoassay, and affinity column assay.
- In vitro hydrolytic stability studies under physiological conditions.
Main Results:
- Misonidazole was successfully conjugated to the antibody at varying loading levels (3-68 mol drug/mol antibody).
- Antibody binding activity decreased with increased drug loading but remained significant.
- Conjugates demonstrated hydrolytic stability with a half-life of 4 days.
Conclusions:
- Misonidazole-antibody conjugates retain significant binding activity, making them suitable for targeted delivery.
- An optimal loading factor for misonidazole-antibody conjugates in immunochemotherapy is between 8 and 15.
- These conjugates show promise for enhancing radiosensitization in colorectal cancer treatment.